Results 31 to 40 of about 123,264 (354)

Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance. [PDF]

, 2018
Expression of the chromatin-associated protein HMGA2 correlates with progression, metastasis and therapy resistance in pancreatic ductal adenocarcinoma (PDAC). Hmga2 has also been identified as a marker of a transient subpopulation of PDAC cells that has
Chiou, Shin-Heng, Dorsch, Madeleine, Grüner, Barbara M, Koong, Albert C, Kozak, Margaret M, Kusch, Eva, Naranjo, Santiago, Winslow, Monte M   +7 more
core   +1 more source

A case report of a collision tumor composed of pancreatic ductal adenocarcinoma and peri-pancreatic mucosa-associated lymphoid tissue lymphoma

World Journal of Surgical Oncology, 2023
Background Collision tumors are composed of two distinct tumor components. Collision tumors composed of pancreatic ductal adenocarcinoma and malignant lymphoma occurring in the pancreas have not been previously described in the scientific literature.
Ryuji Hirai, Ken-ichi Omae, Mitsuko Yodoya, Syunji Fujie, Masayoshi Fujii, Kazuma Iwata, Kentaro Imanishi, Eisuke Kurihara, Kazuhiro Yoshida, Masaru Jida, Kazuyasu Kobayashi, Yoshiaki Kanaya, Syuichiro Maruyama   +12 more
doaj   +1 more source

Biomarkers in pancreatic ductal adenocarcinoma

Clinical and Translational Oncology, 2017
Pancreatic ductal adenocarcinoma (PDAC) is currently the third most frequent form of malignancy. The role of biomarkers in the diagnostic and therapeutic strategy of cancer is constantly expanding. Translational research is already changing paradigms in tumours encompassing from early diagnosis to precision medicine in advanced disease.
J. Gallego, C. López, R. Pazo-Cid, F. López-Ríos, A. Carrato   +4 more
openaire   +4 more sources

Advances in the management of pancreatic ductal adenocarcinoma [PDF]

Canadian Medical Association Journal, 2021
KEY POINTS The incidence of pancreatic ductal adenocarcinoma (PDAC) is rising and PDAC is projected to become the third leading cause of cancer death in Canada.[1][1] Although risk factors for PDAC are known, the reason for its rising incidence is not.
Steven Gallinger, Grainne M. O'Kane, Farah Ladak   +2 more
openaire   +3 more sources

Regulation of pancreatic cancer aggressiveness by stromal stiffening [PDF]

, 2016
No abstract ...
A Neesse, AD Rhim, BC Özdemir, H Laklai, I Barbieri, JJ Lee, JK Mouw, JM Bailey, Michael F Olson, Nicola Rath, P Bailey, SR Hingorani, SR Hingorani, V Sanz-Moreno   +13 more
core   +1 more source

How fibrosis influences imaging and surgical decisions in pancreatic cancer

Frontiers in Physiology, 2012
Our understanding of pancreatic ductal adenocarcinoma is shifting away from a disease of malignant ductal cells-only, towards a complex system where tumor evolution is a result of interaction of cancer cells with their microenvironment.
Mert eErkan, Simone eHausmann, Christoph W Michalski, Melissa eSchlitter, Alexander A Fingerle, Martin eDobritz, Helmut eFriess, Jörg eKleeff   +7 more
doaj   +1 more source

Metformin as an Adjunctive Therapy for Pancreatic Cancer: A Review of the Literature on Its Potential Therapeutic Use [PDF]

, 2018
Pancreatic ductal adenocarcinoma has the worst prognosis of any cancer. New adjuvant chemotherapies are urgently required, which are well tolerated by patients with unresectable cancers.
A Hwang, A Isakovic, A Jo, A Kim, A Somogyi, A Tomimoto, A Vazquez-Martin, A Woods, AD Morris, Andrew R. Hart, AT Nies, B Liu, CJ Bailey, CJ Bailey, CJ Currie, CM Ambe, D Iliopoulos, D Ish-Shalom, DG Hardie, DG Hardie, DG Hardie, EJ Brown, G Zhou, GG Graham, H Takane, HA Hirsch, I Tkac, IB Sahra, IN Alimova, J Muller, JPT Higgins, K Cusi, K Inoki, K Polyak, K Zhou, K Zhou, L-W Wang, LA Cantrell, LL Campbell, M Bodmer, M Cerullo, M Pollak, M Reni, M Zhou, MA Frouws, MA Tempero, ML Goalstone, MM Kozak, MN Cook, MR Owen, N Leeuwen van, N Sadeghi, Philip J. Broadhurst, R Chaiteerakij, RC Turner, RM Memmott, S Amin, S Kordes, S Singh, S Wullschleger, SA Hawley, SE Kahn, SH Lee, SW Yee, T Conroy, T Conroy, T Higurashi, VN Anisimov, X Huang, X-S Deng, Y Choi, Y Shi, Y Zhao, Y Zhuang   +73 more
core   +1 more source

Label-free proteomics reveals serum proteins whose levels differ between pancreatic ductal adenocarcinoma patients with short or long survival

Tumor Biology, 2020
Pancreatic ductal adenocarcinoma is the most common and aggressive type of pancreatic cancer, with a 5-year survival rate that is less than 10%. New biomarkers to aid in predicting the prognosis of pancreatic ductal adenocarcinoma patients are needed ...
Matilda Holm, Mayank Saraswat, Sakari Joenväärä, Hanna Seppänen, Risto Renkonen, Caj Haglund   +5 more
doaj   +1 more source

An Immunological Glance on Pancreatic Ductal Adenocarcinoma [PDF]

International Journal of Molecular Sciences, 2020
Pancreatic ductal adenocarcinoma (PDAC) has still a dismal prognosis. Different factors such as mutational landscape, intra- and intertumoral heterogeneity, stroma, and immune cells impact carcinogenesis of PDAC associated with an immunosuppressive microenvironment. Different cell types with partly opposing roles contribute to this milieu.
Michael Karl Melzer, Frank Arnold, Katja Stifter, Friedemann Zengerling, Ninel Azoitei, Thomas Seufferlein, Christian Bolenz, Alexander Kleger   +7 more
openaire   +2 more sources

Photodynamic Therapy for Pancreatic Ductal Adenocarcinoma [PDF]

Cancers, 2021
Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal of human cancers. Clinical trials of various chemotherapy, radiotherapy, targeted agents and combination strategies have generally failed to provide meaningful improvement in survival for patients with unresectable disease.
Vida Karimnia, Frank J. Slack, Jonathan P. Celli   +2 more
openaire   +2 more sources